NCT07412613 2026-04-22
Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Akeso
Phase 3 Recruiting
Akeso
M.D. Anderson Cancer Center
CStone Pharmaceuticals
Astellas Pharma Inc
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC